From: The impact of Zn-doped synthetic polymer materials on bone regeneration: a systematic review
Source | Cell types | Promoting Zn2+ content | Inhibiting Zn2+ content | References |
---|---|---|---|---|
Adipose | Swine ASC | 0.04–0.08 mM for mineral nodule formation | Above 0.08 mM for cell growth | [10] |
pASCs | Below 0.04 mM for cell number and metabolic activity | – | [11] | |
Bone | mBMSCs | 10.91–27.15 μM for proliferation and ALP activity | 128.58 μM for ALP activity | [12] |
MC3T3-E1 osteoblasts | 10−6–10−4 M for osteoprotegerin, Runx-2, and regucalcin mRNA expression | – | ||
Human osteoblast-like cell line SaOS-2 | 1–10 μM for ALP expression and mineral deposition | Exceeding 25 μM for the same functions | ||
Osteoclast | 10−12–10−4 mol/L for cell activity | Higher than 10−4 to promote the proliferation of TRAP-positive cells | ||
Osteoblasts and primary murine bone marrow stromal cells | Lower than 10−9 M for proliferation | Lower than 10−9 M for osteogenic and adipogenic differentiation | ||
rBMSCs | 10−5 mol/L to achieve the best osteogenic effect | – | ||
Vascular | Endothelial cells | 1.1 mg/L for proliferation | 2.7 mg/L to cause cytotoxicity | |
Vascular smooth muscle cells | 60–80 μM for cell adhesion, spreading, proliferation, and migration | 80–120 μM for the same cellular functions | ||
Abdomen | RAW264.7 | 10–250 μM to suppress osteoclastogenesis | – |